Skip to main content
Top
Published in: Internal and Emergency Medicine 5/2017

01-08-2017 | IM - ORIGINAL

Usefulness of procalcitonin in differentiating Candida and bacterial blood stream infections in critically ill septic patients outside the intensive care unit

Authors: Filippo Pieralli, Lorenzo Corbo, Arianna Torrigiani, Dario Mannini, Elisa Antonielli, Antonio Mancini, Francesco Corradi, Fabio Arena, Alberto Moggi Pignone, Alessandro Morettini, Carlo Nozzoli, Gian Maria Rossolini

Published in: Internal and Emergency Medicine | Issue 5/2017

Login to get access

Abstract

We aimed to explore the role of procalcitonin (PCT) for the diagnosis of Candida spp. bloodstream infections in a population of critically ill septic patients admitted to internal medicine units. This is a retrospective case–control study considering all cases of candidemia identified in three internal medicine units, from January 1st 2012 to May 31st 2016. For each case of candidemia, two patients with bacteremic sepsis were included in the study as control cases. The end point of the study was to evaluate the diagnostic performance of PCT for the diagnosis of Candida spp. blood stream infections in patients with objectively documented sepsis. Sixty-four patients with candidemia and 128 controls with bacteremia were enrolled. Median and interquartile range (IQR) PCT values are significantly lower in patients with candidemia (0.73; IQR 0.26–1.85 ng/mL) than in those with bacteremia (4.48; IQR 1.10–18.26 ng/mL). At ROC curve analysis, values of PCT greater than 2.5 ng/mL had a negative predictive value (NPV) of 98.3% with an AUC of 0.76 (0.68–0.84 95% CI) for the identification of Candida spp. from blood cultures. At multivariate analysis, a PCT value <2.5 ng/mL showed an odds ratio of 8.57 (95% CI 3.09–23.70; p < 0.0001) for candidemia. In septic patients at risk of Candida infection, a PCT value lower than 2.5 ng/mL should raise the suspicion of candidemia, adding value for considering prompt initiation of antifungal therapy.
Literature
2.
go back to reference Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317CrossRefPubMed Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317CrossRefPubMed
3.
4.
go back to reference Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B et al (2007) Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 58(3):325–331 (Elsevier) CrossRefPubMed Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B et al (2007) Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 58(3):325–331 (Elsevier) CrossRefPubMed
5.
go back to reference Falagas ME, Apostolou KE, Pappas VD (2006) Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25(7):419–425CrossRefPubMed Falagas ME, Apostolou KE, Pappas VD (2006) Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25(7):419–425CrossRefPubMed
6.
go back to reference Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43(1):25–31CrossRefPubMed Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43(1):25–31CrossRefPubMed
7.
go back to reference Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56(9):1284–1292CrossRefPubMed Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56(9):1284–1292CrossRefPubMed
8.
go back to reference Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37CrossRefPubMed Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37CrossRefPubMed
9.
go back to reference Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503–535CrossRefPubMed Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48(5):503–535CrossRefPubMed
10.
go back to reference Held J, Kohlberger I, Rappold E, Busse Grawitz A, Häcker G (2013) Comparison of (1->3)-β-d-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol 51(4):1158–1164CrossRefPubMedPubMedCentral Held J, Kohlberger I, Rappold E, Busse Grawitz A, Häcker G (2013) Comparison of (1->3)-β-d-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol 51(4):1158–1164CrossRefPubMedPubMedCentral
11.
go back to reference Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10(5):882–885PubMedPubMedCentral Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10(5):882–885PubMedPubMedCentral
13.
go back to reference Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (London, England) 341(8844):515–518 (internet) CrossRef Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (London, England) 341(8844):515–518 (internet) CrossRef
14.
go back to reference Brodská H, Malíčková K, Adámková V, Benáková H, Šťastná MM, Zima T (2013) Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin Exp Med 13(3):165–170CrossRefPubMed Brodská H, Malíčková K, Adámková V, Benáková H, Šťastná MM, Zima T (2013) Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis. Clin Exp Med 13(3):165–170CrossRefPubMed
15.
go back to reference Guo SY, Zhou Y, Hu QF, Yao J, Wang H (2015) Procalcitonin is a marker of Gram-negative bacteremia in patients with sepsis. Am J Med Sci 349(6):499–504CrossRefPubMedPubMedCentral Guo SY, Zhou Y, Hu QF, Yao J, Wang H (2015) Procalcitonin is a marker of Gram-negative bacteremia in patients with sepsis. Am J Med Sci 349(6):499–504CrossRefPubMedPubMedCentral
16.
go back to reference Christ-Crain M, Müller B (2005) Procalcitonin in bacterial infections—hype, hope, more or less? Swiss Med Wkly 135(31–32):451–460PubMed Christ-Crain M, Müller B (2005) Procalcitonin in bacterial infections—hype, hope, more or less? Swiss Med Wkly 135(31–32):451–460PubMed
17.
go back to reference Pieralli F, Vannucchi V, Mancini A, Antonielli E, Luise F, Sammicheli L et al (2015) Procalcitonin kinetics in the first 72 hours predicts 30-day mortality in severely ill septic patients admitted to an intermediate care unit. J Clin Med Res 7(9):706–713CrossRefPubMedPubMedCentral Pieralli F, Vannucchi V, Mancini A, Antonielli E, Luise F, Sammicheli L et al (2015) Procalcitonin kinetics in the first 72 hours predicts 30-day mortality in severely ill septic patients admitted to an intermediate care unit. J Clin Med Res 7(9):706–713CrossRefPubMedPubMedCentral
18.
go back to reference Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK et al (2014) Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes 7:458CrossRefPubMedPubMedCentral Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK et al (2014) Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes 7:458CrossRefPubMedPubMedCentral
19.
go back to reference Martini A, Gottin L, Menestrina N, Schweiger V, Simion D, Vincent J-L (2010) Procalcitonin levels in surgical patients at risk of candidemia. J Infect 60(6):425–430CrossRefPubMed Martini A, Gottin L, Menestrina N, Schweiger V, Simion D, Vincent J-L (2010) Procalcitonin levels in surgical patients at risk of candidemia. J Infect 60(6):425–430CrossRefPubMed
20.
go back to reference Charles PE, Dalle F, Aho S, Quenot J-P, Doise J-M, Aube H et al (2006) Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 32(10):1577–1583CrossRefPubMed Charles PE, Dalle F, Aho S, Quenot J-P, Doise J-M, Aube H et al (2006) Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 32(10):1577–1583CrossRefPubMed
21.
go back to reference Montagna MT, Coretti C, Caggiano G (2011) Procalcitonin: a possible marker of invasive fungal infection in high risk patients? J Prev Med Hyg. 52(1):38–39PubMed Montagna MT, Coretti C, Caggiano G (2011) Procalcitonin: a possible marker of invasive fungal infection in high risk patients? J Prev Med Hyg. 52(1):38–39PubMed
22.
go back to reference Cortegiani A, Russotto V, Montalto F, Foresta G, Accurso G, Palmeri C et al (2014) Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol 14:9CrossRefPubMedPubMedCentral Cortegiani A, Russotto V, Montalto F, Foresta G, Accurso G, Palmeri C et al (2014) Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol 14:9CrossRefPubMedPubMedCentral
23.
go back to reference Jin M, Khan AI (2010) Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. Lab Med 41(3):173–177 (The Oxford University Press) CrossRef Jin M, Khan AI (2010) Procalcitonin: uses in the clinical laboratory for the diagnosis of sepsis. Lab Med 41(3):173–177 (The Oxford University Press) CrossRef
24.
go back to reference Frank M, Sivagnanaratnam A, Bernstein J (2015) Nutritional assessment in elderly care: a MUST!. BMJ Qual Improv Reports 4(1):1–3CrossRef Frank M, Sivagnanaratnam A, Bernstein J (2015) Nutritional assessment in elderly care: a MUST!. BMJ Qual Improv Reports 4(1):1–3CrossRef
25.
go back to reference Tavares E, Maldonado R, Ojeda ML, Miñano FJ (2005) Circulating inflammatory mediators during start of fever in differential diagnosis of Gram-negative and Gram-positive infections in leukopenic rats. Clin Diagn Lab Immunol 12(9):1085–1093PubMedPubMedCentral Tavares E, Maldonado R, Ojeda ML, Miñano FJ (2005) Circulating inflammatory mediators during start of fever in differential diagnosis of Gram-negative and Gram-positive infections in leukopenic rats. Clin Diagn Lab Immunol 12(9):1085–1093PubMedPubMedCentral
26.
go back to reference Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B (2004) Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 32(8):1715–1721CrossRefPubMed Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B (2004) Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 32(8):1715–1721CrossRefPubMed
27.
go back to reference Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306(23):2594–2605CrossRefPubMedPubMedCentral Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306(23):2594–2605CrossRefPubMedPubMedCentral
28.
go back to reference Molter GP, Soltész S, Kottke R, Wilhelm W, Biedler A, Silomon M (2003) Procalcitonin plasma concentrations and systemic inflammatory response following different types of surgery. Anaesthesist 52(3):210–217CrossRefPubMed Molter GP, Soltész S, Kottke R, Wilhelm W, Biedler A, Silomon M (2003) Procalcitonin plasma concentrations and systemic inflammatory response following different types of surgery. Anaesthesist 52(3):210–217CrossRefPubMed
29.
go back to reference Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51(12):4167–4172CrossRefPubMedPubMedCentral Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51(12):4167–4172CrossRefPubMedPubMedCentral
30.
go back to reference Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49(9):3640–3645CrossRefPubMedPubMedCentral Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49(9):3640–3645CrossRefPubMedPubMedCentral
31.
go back to reference De Rosa FG, Corcione S, Filippini C, Raviolo S, Fossati L, Montrucchio C et al (2015) The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards. PLoS One 10(5):1–9 De Rosa FG, Corcione S, Filippini C, Raviolo S, Fossati L, Montrucchio C et al (2015) The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards. PLoS One 10(5):1–9
Metadata
Title
Usefulness of procalcitonin in differentiating Candida and bacterial blood stream infections in critically ill septic patients outside the intensive care unit
Authors
Filippo Pieralli
Lorenzo Corbo
Arianna Torrigiani
Dario Mannini
Elisa Antonielli
Antonio Mancini
Francesco Corradi
Fabio Arena
Alberto Moggi Pignone
Alessandro Morettini
Carlo Nozzoli
Gian Maria Rossolini
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 5/2017
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-017-1627-7

Other articles of this Issue 5/2017

Internal and Emergency Medicine 5/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.